Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

BACKGROUND: We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS dis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Gadgeel, Shirish, Shaw, Alice T, Barlesi, Fabrice, Crinò, Lucio, Yang, James Chih-Hsin, Dingemans, Anne-Marie C, Kim, Dong-Wan, de Marinis, Filippo, Schulz, Mathias, Liu, Shiyao, Gupta, Ravindra, Kotb, Ahmed, Ou, Sai-Hong Ignatius
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2018
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765233/
https://ncbi.nlm.nih.gov/pubmed/29149104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.395
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados